Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review

References

• Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clini Microbiol Infect. 2012;18:7–11. doi:10.1111/j.1469-0691.2012.03937.x.
   PubMed Web of Science ®Google Scholar
• Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr. 2002;161:188–95.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Pneumococcal Disease - Risk Factors; 2017. https://www.cdc.gov/pneumococcal/clinicians/risk-factors.html .
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Disease factsheet about pneumococcal disease; 2020. https://www.ecdc.europa.eu/en/pneumococcal-disease/facts.
   Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine. 2009;27(29):3802–10. doi:10.1016/j.vaccine.2009.04.021.
   PubMed Web of Science ®Google Scholar
• Htar MTT, Christopoulou D, Schmitt H-J. Pneumococcal serotype evolution in Western Europe. BMC infect dis. 2015;15(1):419.
   PubMedGoogle Scholar
• The World Health Organization (WHO). Vaccine in National Immunization Programme Update October 2020; 2020. https://cdn.who.int/media/docs/default-source/immunization/hpv/vaccineintrostatus.pdf?sfvrsn=a705e49c_5 .
   Google Scholar
• Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’brien KL, Moore MR, Serotype Replacement Study Group. Serotype-Specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.
   PubMed Web of Science ®Google Scholar
• Hanquet G, Krizova P, Valentiner-Branth P, Ladhani SN, Nuorti JP, Lepoutre A, Mereckiene J, Knol M, Winje BA, Ciruela P, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473–82. doi:10.1136/thoraxjnl-2018-211767.
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197–e209. doi:10.1016/j.ijid.2009.05.010.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–68. doi:10.1016/S1473-3099(11)70090-1.
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–16. doi:10.1097/00006454-200301000-00006.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127–31.
   PubMed Web of Science ®Google Scholar
• Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, et al. Cost-Effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011;29(31):4963–72. doi:10.1016/j.vaccine.2011.04.111.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502. doi:10.1016/S0140-6736(06)69637-2.
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination CRD. Systematic Reviews - CRD’s guidance for undertaking reviews in health care; 2009.
   Google Scholar
• Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Preferred Reporting Items for Systematic Reviews and Meta-Analyses. http://www.prisma-statement.org/ .
   Google Scholar
• National Immunization Technical Advisory Groups. 2020; https://www.nitag-resource.org/.
   Google Scholar
• International Network of Agencies for Health Technology Assessment (INAHTA). Members List. http://www.inahta.org/members/members_list/.
   Google Scholar
• European Network for Health Technology Assessment EUnetHTA Network; 2020 Jun 02. https://eunethta.eu/about-eunethta/eunethtanetwork/.
   Google Scholar
• Comissão Técnica de Vacinação (CTV). Parecer técnico sobre a introdução da vacina pneumocócica conjugada heptavalente no PNV em 2009; 2008.
   Google Scholar
• Haut Conseil de la santé publique. Avis relatif à une éventuelle évolution des recommandations de vaccination des nourrissons contre les infections invasives à pneumocoque par le vaccin pneumococcique conjugué 13-valent; 2012.
   Google Scholar
• Haute Autorité de Santé (HAS). Place du vaccin SYNFLORIX™ dans la stratégie vaccinale contre les infections à pneumocoques chez l’enfant âgé de moins de 5 ans; 2018.
   Google Scholar
• Gezondheidsraad (Health Council of the Netherlands). Algemene vaccinatie tegen meningokokken C en pneumokokken; 2002.
   Google Scholar
• Gezondheidsraad (Health Council of the Netherlands). Dossier vaccinatie van zuigelingen tegen pneumokokkeninfecties; 2005.
   Google Scholar
• Bundesministerium Für Soziales G. Pflege und Kosumentschutz. Impfplan Österreich 2020; 2020.
   Google Scholar
• Council SH. Vaccinatie tegen pneumokokken; 2018.
   Google Scholar
• Gezondheidszorrg) KFKVD. Cost-Effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood; 2011.
   Google Scholar
• KCE (Federaal Kenniscentrum voor de Gezondheidszorrg). Effects and costs of pneumococcal conjugate vaccination of Belgian children; 2006.
   Google Scholar
• Vucina VV, et al. Cost-Effectiveness of pneumococcal conjugate vaccination in Croatia. Vaccine. 2015;33(Suppl 1):A209–18.
   PubMedGoogle Scholar
• Sundhetsstyrelsen. ANBEFALING OM INDFØRELSE AF PNEUMOKOKVACCINATION I DET DANSKE BØRNEVACCINATIONSPROGRAM; 2007.
   Google Scholar
• Tartu University Department of Public Health. Pneumokokkinfektsioonivastase vaktsineerimise kulutõhusus; 2015.
   Google Scholar
• THL - Terveyden ja hyvinvoinnin laitos. Pneumokokkirokotus strategiat; 2018.
   Google Scholar
• KTL (National Public Health Institute). Kansanterveyslaitoksen asettaman lasten pneumokokkirokotustyöryhmän selvitys [Report of the Pediatric Pneumococcal Vaccination Task Force set up by the National Institute of Public Health]; 2008.
   Google Scholar
• Haut Conseil de la santé publique. Avis relatif à la vaccination par le vaccin pneumococcique conjugué 13-valent; 2009.
   Google Scholar
• Haut Conseil de la santé publique. Avis relatif à la réévaluation des recommandations vaccinales du vaccin anti-pneumococcique conjugué heptavalent dans les suites de l’extension d’AMM1 à la prévention des otites moyennes aiguës et des pneumonies à pneumocoque; 2008.
   Google Scholar
• Conseil supérieur d’hygiène publique de France. Avis du Conseil supérieur d’hygiène publique de France (section maladies transmissibles) relatif à la vaccination par le vaccin anti-pneumococcique conjugué chez les enfants de moins de deux ans et les enfants de deux à cinq ans (séance du 19 mai 2006); 2006.
   Google Scholar
• STIKO (Ständigen Impfkommission) at Robert Koch-Institut. Wissenschaftliche Begründung zur Änderung der Pneumokokken-Impfempfehlung für Säuglinge; 2015.
   Google Scholar
• Claes C, Reinert RR, Vauth C, Greiner W. Health technology assessment heptavalenter pneumokokkenkonjugat-impfstoff (PCV7); 2008.
   Google Scholar
• STIKO (Ständigen Impfkommission) at Robert Koch-Institut. Begründung der STIKO-Empfehlungen zur Impfung gegen Pneumokokken und Meningokokken vom Juli 2006: Pneumokokken-Impfung mit 7-valentem Konjugatimpfstoff für Kinder unter 2 Jahren; 2006.
   Google Scholar
• Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information (DIMDI). Medizinische und ökonomische Effektivität der Pneumokokkenimpfung für Säuglinge und Kleinkinder; 2005.
   Google Scholar
• National Centre for Pharmacoeconomics. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland; 2012.
   Google Scholar
• Tilson L, Usher C, Butler K, Fitzsimons J, O’Hare F, Cotter S, O’Flanagan D, Johnson H, Barry M. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Value Health. 2008;11(5):898–903.
   PubMed Web of Science ®Google Scholar
• National Centre for Pharmacoeconomics. Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland; 2007.
   Google Scholar
• Società Italiana d’Igiene Medicina Preventiva e Sanità Pubblica. Calendario Vaccinale per la Vita 4° edizione 2019; 2019.
   Google Scholar
• Ministero della Salute. Piano Nazionale Prevenzione Vaccinale; 2017.
   Google Scholar
• CSMI. Avis du CSMI pour la vaccination universelle contre le pneumocoque : vaccin 10 ou 13-valent ? 2016.
   Google Scholar
• CSMI. Vaccination universelle des nourrissons et des enfants contre les infections invasives à Streptococcus pneumoniae; 2011.
   Google Scholar
• Gezondheidsraad (Health Council of the Netherlands). Dossier vaccinatie van zuigelingen tegen pneumokokkeninfecties; 2013.
   Google Scholar
• Gezondheidsraad (Health Council of the Netherlands). Dossier vaccinatie van zuigelingen tegen pneumokokkeninfecties; 2010.
   Google Scholar
• Bos JM, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther. 2003;25(10):2614–30. doi:10.1016/S0149-2918(03)80322-3.
   PubMed Web of Science ®Google Scholar
• Wisloff T, Abrahamsen TG, Bergsaker MAR, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine. 2006;24(29–30):5690–99. doi:10.1016/j.vaccine.2006.04.042.
   PubMed Web of Science ®Google Scholar
• Agencja Oceny Technologii Medycznych. Prezesa Agencji Oceny Technologii Medycznych w sprawie objęcia refundacją produktu leczniczego Prevenar 13, szczepionka przeciw pneumokokom polisacharydowa, skoniugowana (13-walentna, adsorbowana); zawiesina do wstrzykiwań; 0,5 ml; 1 ampułko-strzykawka (0,5 ml) + 1 igła; kod EAN: 5909990737420; 2014.
   Google Scholar
• Grupo de Trabajo de Neumococo. Nuevas vacunas antineumocócicas conjugadas; 2009.
   Google Scholar
• Grupo de trabajo de la Ponencia de Registro y Programa de Vacunas. Enfermedad invasora por streptococcus pneumoniae; 2006.
   Google Scholar
• Socialstyrelsen. A cost-effectiveness analysis of introducing pneumococcal vaccine in the Swedish vaccination programme; 2008.
   Google Scholar
• Socialstyrelsen. Bör Sverige införa ett sju-valent konjugerat pneumokockvaccin (PCV7) i det allmänna barnvaccinations-programmet? 2008.
   Google Scholar
• Bundesamt für Gesundheit und Eidgenössische Kommission für Impffragen. Schweizerischer Impfplan 2020; 2020.
   Google Scholar
• Bundesamt für Gesundheit (BAG). Pneumokokkenimpfung von Kindern unter 5 Jahren neu als Basisimpfung empfohlen; 2019.
   Google Scholar
• Bundesamt für Gesundheit (BAG). Empfehlungen zur Pneumokokkenimpfung bei Kindern unter 5 Jahren: Wechsel vom 7- zum 13-valenten konjugierten Impfstoff; 2010.
   Google Scholar
• Bundesamt für Gesundheit (BAG). Empfehlungen zur Pneumokokkenimpfung bei Kindern unter 5 Jahren; 2007.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation (JCVI). Minute of the meeting held on 05 June 2019; 2019.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation (JCVI). Minute of the meeting on 07 February 2018; 2018.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation (JCVI). Minute of the meeting on 04 October 2017; 2017.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation (JCVI). Minute of the meeting on 04 June 2014; 2014.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation (JCVI). Proposed changes to the routine childhood immunisation schedule; 2005.
   Google Scholar
• Vaccine European New Integrated Collaboration Effort (VENICE) II. HTA for pneumococcal vaccines: Survey on the availability of Health Technology Assessment in the field of pneumococcal vaccines and availability of information to perform one. VENICE II, in collaboration with the ECDC; 2011.
   Google Scholar
• Nohynek H, Wichmann O, D’Ancona F. National advisory groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19(12):1096–105. doi:10.1111/1469-0691.12315.
   PubMed Web of Science ®Google Scholar
• Takla A, Wichmann O, Carrillo-Santisteve P, Cotter S, Lévy-Bruhl D, Paradowska-Stankiewicz I, Valentiner-Branth P, D’-Ancona F. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. Euro Surveill. 2015;20(9). doi:10.2807/1560-7917.ES2015.20.9.21049.
   PubMedGoogle Scholar
• Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, Marcos C, Matthews S, Meijer C, Poscia A, Postma M. A report on the status of vaccination in Europe. Vaccine. 2018;36(33):4979–92.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control, Annual epidemiological report for 2017. Surveillance systems overview for 2017 [Internet; Excel workbook]. 2018, ECDC.
   Google Scholar
• Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, Fieuws S, Peetermans WE, Blumental S. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2021;21(1):127–36. doi:10.1016/S1473-3099(20)30173-0.
   PubMed Web of Science ®Google Scholar
• Ray GT. Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe. Expert Rev Pharmacoecon Outcomes Res. 2008;8:373–93.
   PubMedGoogle Scholar
• Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34(3):227–44. doi:10.1007/s40273-015-0335-2.
   PubMed Web of Science ®Google Scholar
• Schuurman S, et al. Abstract: human papillomavirus gender-neutral vaccination recommendations: do health technology assessment agencies or national immunization technical advisory groups include head and neck cancer burden in their appraisal? 33rd International Papillomavirus Conference; 2020 Jul 20–24; Virtual.
   Google Scholar
• St-Martin G, Lindstrand A, Sandbu S, Fischer TK. Selection and Interpretation of Scientific Evidence in Preparation for Policy Decisions: A Case Study Regarding Introduction of Rotavirus Vaccine Into National Immunization Programs in Sweden, Norway, Finland, and Denmark. Front Public Health. 2018;6:131.
   PubMed Web of Science ®Google Scholar